TCR2 Therapeutics Inc. Common Stock
TCRR
TCRR was delisted on the 31st of May, 2023.
24 hedge funds and large institutions have $136M invested in TCR2 Therapeutics Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 24 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
33.36% more ownership
Funds ownership: 0% → 33.36% (+33%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MAM
MPM Asset Management
Boston,
Massachusetts
|
+$71.8M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$32.1M |
| 3 |
AG
Artal Group
Luxembourg
|
+$8.69M |
| 4 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$8.35M |
| 5 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
+$5.73M |
Top Sellers
TCRR Hedge Fund Activity: Q1 2019 in Review
24 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in TCR2 Therapeutics Inc. Common Stock (TCRR) for Q1 2019, worth a combined $136M.
Buyers outnumbered sellers: 24 funds opened new TCRR positions and 0 closed out — a net gain of 24 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was MPM Asset Management, opening a new position worth an estimated $71.8M.
- 24 institutional investors held TCR2 Therapeutics Inc. Common Stock (TCRR) as of Q1 2019, up from 0 in Q4 2018.
- Funds reported $136M of TCR2 Therapeutics Inc. Common Stock stock for Q1 2019.
- 24 funds opened new TCR2 Therapeutics Inc. Common Stock positions in Q1 2019 and 0 closed out, a net change of +24 holders.
- The largest TCR2 Therapeutics Inc. Common Stock buyer in Q1 2019 was MPM Asset Management, an estimated $71.8M added.
Based on aggregated 13F filings for Q1 2019.